Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study

被引:95
作者
Patil, Vijay Maruti [1 ]
Noronha, Vanita [1 ]
Menon, Nandini [1 ]
Rai, Rahul [1 ]
Bhattacharjee, Atanu [2 ]
Singh, Ajay [1 ]
Nawale, Kavita [1 ]
Jogdhankar, Shweta [1 ]
Tambe, Rupali [1 ]
Dhumal, Sachin [1 ]
Sawant, Riddhi [1 ]
Alone, Mitali [1 ]
Karla, Devanshi [1 ]
Peelay, Zoya [1 ]
Pathak, Shruti [1 ]
Balaji, Arun [3 ]
Kumar, Suman [4 ]
Purandare, Nilendu [5 ]
Agarwal, Archi [5 ]
Puranik, Ameya [5 ]
Mahajan, Abhishek [4 ]
Janu, Amit [4 ]
Kumar Singh, Gunjesh [1 ]
Mittal, Neha [6 ]
Yadav, Subhash [6 ]
Banavali, Shripad [1 ]
Prabhash, Kumar [1 ]
机构
[1] Tata Mem Hosp, Homi Bhabha Natl Inst HBNI, Dept Med Oncol, Mumbai, India
[2] Ctr Canc Epidemiol, Homi Bhabha Natl Inst HBNI, Tata Mem Ctr, Sect Biostat, Mumbai, India
[3] Tata Mem Hosp, Homi Bhabha Natl Inst HBNI, Dept Speech & Therapy, Mumbai, India
[4] Tata Mem Hosp, Homi Bhabha Natl Inst HBNI, Dept Radiol, Mumbai, India
[5] Tata Mem Hosp, Homi Bhabha Natl Inst HBNI, Dept Nucl Med, Mumbai, India
[6] Tata Mem Hosp, Homi Bhabha Natl Inst HBNI, Dept Pathol, Mumbai, India
关键词
SQUAMOUS-CELL CARCINOMA; METRONOMIC CHEMOTHERAPY; OPEN-LABEL; NIVOLUMAB; RECURRENT; CETUXIMAB; SAFETY; GUIDELINES; CISPLATIN; SURVIVAL;
D O I
10.1200/JCO.22.01015
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSEThe regimens approved for the treatment of advanced head and neck squamous cell carcinoma are accessible to only 1%-3% of patients in low- and middle-income countries because of their cost. In our previous study, metronomic chemotherapy improved survival in this setting. Retrospective data suggest that a low dose of nivolumab may be efficacious. Hence, we aimed to assess whether the addition of low-dose nivolumab to triple metronomic chemotherapy (TMC) improved overall survival (OS).METHODSThis was a randomized phase III superiority study. Adult patients with recurrent or newly diagnosed advanced head and neck squamous cell carcinoma being treated with palliative intent with an Eastern Cooperative Oncology Group performance status of 0-1 were eligible. Patients were randomly assigned 1:1 to TMC consisting of oral methotrexate 9 mg/m(2) once a week, celecoxib 200 mg twice daily, and erlotinib 150 mg once daily, or TMC with intravenous nivolumab (TMC-I) 20 mg flat dose once every 3 weeks. The primary end point was 1-year OS.RESULTSOne hundred fifty-one patients were randomly assigned, 75 in TMC and 76 in the TMC-I arm. The addition of low-dose nivolumab led to an improvement in the 1-year OS from 16.3% (95% CI, 8.0 to 27.4) to 43.4% (95% CI, 30.8 to 55.3; hazard ratio, 0.545; 95% CI, 0.362 to 0.820; P = .0036). The median OS in TMC and TMC-I arms was 6.7 months (95% CI, 5.8 to 8.1) and 10.1 months (95% CI, 7.4 to 12.6), respectively (P = .0052). The rate of grade 3 and above adverse events was 50% and 46.1% in TMC and TMC-I arms, respectively (P = .744).CONCLUSIONTo our knowledge, this is the first-ever randomized study to demonstrate that the addition of low-dose nivolumab to metronomic chemotherapy improved OS and is an alternative standard of care for those who cannot access full-dose checkpoint inhibitors.
引用
收藏
页码:222 / +
页数:12
相关论文
共 34 条
  • [1] Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
    Akinleye, Akintunde
    Rasool, Zoaib
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (01)
  • [2] [Anonymous], DRAFT GUID 2020
  • [3] Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
    Brahmer, Julie R.
    Drake, Charles G.
    Wollner, Ira
    Powderly, John D.
    Picus, Joel
    Sharfman, William H.
    Stankevich, Elizabeth
    Pons, Alice
    Salay, Theresa M.
    McMiller, Tracee L.
    Gilson, Marta M.
    Wang, Changyu
    Selby, Mark
    Taube, Janis M.
    Anders, Robert
    Chen, Lieping
    Korman, Alan J.
    Pardoll, Drew M.
    Lowy, Israel
    Topalian, Suzanne L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) : 3167 - 3175
  • [4] Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
    Burtness, Barbara
    Harrington, Kevin J.
    Greil, Richard
    Soulieres, Denis
    Tahara, Makoto
    de Castro, Gilberto, Jr.
    Psyrri, Amanda
    Baste, Neus
    Neupane, Prakash
    Bratland, Ase
    Fuereder, Thorsten
    Hughes, Brett G. M.
    Mesia, Ricard
    Ngamphaiboon, Nuttapong
    Rordorf, Tamara
    Ishak, Wan Zamaniah Wan
    Hong, Ruey-Long
    Mendoza, Rene Gonzalez
    Roy, Ananya
    Zhang, Yayan
    Gumuscu, Burak
    Cheng, Jonathan D.
    Jin, Fan
    Rischin, Danny
    [J]. LANCET, 2019, 394 (10212) : 1915 - 1928
  • [5] ESMO-Magnitude of Clinical Benefit Scale version 1.1
    Cherny, N. I.
    Dafni, U.
    Bogaerts, J.
    Latino, N. J.
    Pentheroudakis, G.
    Douillard, J. -Y.
    Tabernero, J.
    Zielinski, C.
    Piccart, M. J.
    de Vries, E. G. E.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 (10) : 2340 - 2366
  • [6] Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
    Cohen, Ezra E. W.
    Soulieres, Denis
    Le Tourneau, Christophe
    Dinis, Jose
    Licitra, Lisa
    Ahn, Myung-Ju
    Soria, Ainara
    Machiels, Jean-Pascal
    Mach, Nicolas
    Mehra, Ranee
    Burtness, Barbara
    Zhang, Pingye
    Cheng, Jonathan
    Swaby, Ramona F.
    Harrington, Kevin J.
    [J]. LANCET, 2019, 393 (10167) : 156 - 167
  • [7] Fagan Johannes J, 2021, Am Soc Clin Oncol Educ Book, V41, P1, DOI 10.1200/EDBK_320923
  • [8] Nivolumab Exposure-Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non-Small Cell Lung Cancer
    Feng, Yan
    Wang, Xiaoning
    Bajaj, Gaurav
    Agrawal, Shruti
    Bello, Akintunde
    Lestini, Brian
    Finckenstein, Friedrich Graf
    Park, Jong-Soon
    Roy, Amit
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (18) : 5394 - 5405
  • [9] Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
    Ferris, R. L.
    Blumenschein, G., Jr.
    Fayette, J.
    Guigay, J.
    Colevas, A. D.
    Licitra, L.
    Harrington, K.
    Kasper, S.
    Vokes, E. E.
    Even, C.
    Worden, F.
    Saba, N. F.
    Iglesias Docampo, L. C.
    Haddad, R.
    Rordorf, T.
    Kiyota, N.
    Tahara, M.
    Monga, M.
    Lynch, M.
    Geese, W. J.
    Kopit, J.
    Shaw, J. W.
    Gillison, M. L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) : 1856 - 1867
  • [10] Real-World Nivolumab Wastage and Leftover Drug Stability Assessment to Facilitate Drug Vial Optimization for Cost Savings
    Fukudo, Masahide
    Ishikawa, Ryota
    Mishima, Kazuto
    Ono, Takashi
    Matsumoto, Seiji
    Tasaki, Yoshikazu
    [J]. JCO ONCOLOGY PRACTICE, 2020, 16 (10) : 685 - +